A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6 Publication A Physiologically-based Pharmacokinetic Modeling Approach to Predict Disease-drug Interactions: Suppression of CYP3A by IL-6 Elevated cytokine levels are known to downregulate expression and suppress activity of cytochrome P450 enzymes…CertaraApril 10, 2013
A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer Publication A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using…CertaraApril 1, 2013
Effects of Monocarboxylate Transporter Inhibition on the Oral Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone Publication Effects of Monocarboxylate Transporter Inhibition on the Oral Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone Respiratory depression and death secondary to respiratory arrest have occurred after oral overdoses of γ-hydroxybutyrate…CertaraApril 1, 2013
Model-based Drug Development in Oncology: What’s Next? Publication Model-based Drug Development in Oncology: What’s Next? Model-based estimates of tumor growth inhibition (TGI) metrics have the potential to enhance learning in…CertaraApril 1, 2013
Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide Publication Model-supported Development of CS-8635: A Fixed-dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide CS-8635, a fixed-dose triple combination of olmesartan, amlodipine, and hydrochlorothiazide, was developed to address the…CertaraApril 1, 2013
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis Publication Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2,…CertaraMarch 28, 2013
A Poor Metabolizer of Both CYP2C19 and CYP2D6 Identified by Mechanistic Pharmacokinetic Simulation in a Fatal Drug Poisoning Case Involving Venlafaxine Publication A Poor Metabolizer of Both CYP2C19 and CYP2D6 Identified by Mechanistic Pharmacokinetic Simulation in a Fatal Drug Poisoning Case Involving Venlafaxine We present a fatal drug poisoning case involving venlafaxine (VEN). The deceased took his medication…CertaraMarch 10, 2013
Plasma Topiramate Concentrations from Doses Associated with Neuroprotection Against White Matter Injury and Stroke in Two Strains of Rat Pups Publication Plasma Topiramate Concentrations from Doses Associated with Neuroprotection Against White Matter Injury and Stroke in Two Strains of Rat Pups Cerebral white matter (WM) injury and stroke are common neuropathological injuries in newborns with congenital…CertaraMarch 1, 2013
Race and Drug Formulation Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients Publication Race and Drug Formulation Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients Limited mycophenolic acid (MPA) data are available comparing racial influence on mycophenolate mofetil (MMF) and…CertaraMarch 1, 2013
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods—An Analysis of Multiple Sclerosis Data Publication Estimating Time to Disease Progression Comparing Transition Models and Survival Methods—An Analysis of Multiple Sclerosis Data This article reports an analysis that aims to quantify the effect of fingolimod, an oral…CertaraMarch 1, 2013